• Users Online: 223
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2021  |  Volume : 5  |  Issue : 1  |  Page : 1

From the Pen of Editor in Chief

Department of Otolaryngology, PGIMER, Chandigarh, India

Date of Submission17-Jun-2021
Date of Acceptance17-Jun-2021
Date of Web Publication03-Jul-2021

Correspondence Address:
Dr. Naresh K Panda
Department of Otolaryngology, PGIMER, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aiao.aiao_15_21

Rights and Permissions

How to cite this article:
Panda NK. From the Pen of Editor in Chief. Ann Indian Acad Otorhinolaryngol Head Neck Surg 2021;5:1

How to cite this URL:
Panda NK. From the Pen of Editor in Chief. Ann Indian Acad Otorhinolaryngol Head Neck Surg [serial online] 2021 [cited 2022 Aug 7];5:1. Available from: https://www.aiaohns.in/text.asp?2021/5/1/1/320572

Compliments to all the distinguished members of the Governing Council and members of the Indian Academy of Otorhinolaryngology Head and Neck Surgery. The new editorial board of Annals of Indian Academy of Otorhinolaryngology has taken over the mettle of running the affairs of the journal from Prof PSN Murthy the first Editor in chief. He has the distinction of starting the journal after the inception of the academy. The new editorial board takes the opportunity to thank the previous editorial board to take the journal to this position. Prof PSN Murthy would continue to guide us as chairman of the Editorial Board.

The last few months during the COVID pandemic has been a trying time for the specialty of otorhinolaryngology head and neck surgery. We are all fighting the menace of covid associated mucormycosis which has taken epidemic proportions. More than 32,000 cases of mucormycosis have been managed throughout the country by now. The disease has been made notifiable by various state governments and the central government. The rising numbers of mucormycosis amidst the COVID pandemic have come like a storm. Mucormycosis is caused by an ubiquitous fungus of the class zygomycetes and order mucorales and is an invasive fungal disease causing immense morbidity and mortality. The rhino-orbito-cerebral mucormycosis is the most common among the various systems involved. Because of the involvement of eyes and the brain, the rhino-orbital variant of mucormycosis calls for early intervention to prevent a host of permanent disabilities or even, death. The fungus is usually seen in patients with uncontrolled diabetes mellitus, both Type I and Type II. The fact that regular health checkups are still not a norm in the country leads to a situation where we have a lot of patients who are unaware of the diabetic status and presents directly with the complications of the same, including mucormycosis. The uses of steroids to reduce the inflammatory response as part of COVID management have led to a lot of people having deranged sugar levels. This might have also led to a lot of borderline diabetic people to become frankly diabetic and the resultant infections. The role of various immunemodulatory drugs used in COVID management needs evaluation too. The length of hospital stay, use of nasal prongs, and other devices for oxygen delivery and possible breach of sterile conditions of the nasal cavity might have led to cross-infections or hospital-acquired infections. In COVID-negative patients, the behavioral changes caused by the pandemic leading to avoidance of hospital visits and indiscriminate use of domiciliary use of corticosteroids by the patients might have led to less than optimal diabetic care and management.

The standard of care in mucormycosis involves immediate surgical debridement; long-term intravenous Liposomal amphotericin B. Posaconazole has also been used in the cases of recalcitrant or remnant diseases and even as adjuvant therapy due to the shortage of Liposomal amphotericin. I am sure with our collective might we would win the battle against COVID-associated mucormycosis.

The new issue of the journal is going to be online soon. You will be happy to know the first printed version too would be available for circulation among the members of the academy. I would like to thank the team of the editorial board for contributing actively in reviewing the articles on time and be there all the time. I would request all the members of the academy to contribute the articles to the journal which would help us to have more impact in the fraternity. Our tributes to all the corona warriors who have lost their life during the act of service to the patients and mankind. Our salutation to the mucormycosis warriors who are working tirelessly during the last 2 months to take care of the patients.

This article has been cited by
1 Complicating mucormycosis, additional treatment options
EdJ van Hezik
Annals of Indian Academy of Otorhinolaryngology Head and Neck Surgery. 2021; 5(2): 80
[Pubmed] | [DOI]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded179    
    Comments [Add]    
    Cited by others 1    

Recommend this journal